Blackhawk Growth Corp.

BLACKHAWK CEO FREDERICK PELS AND MINDBIO THERAPEUTICS CO-FOUNDER JUSTIN HANKA WILL LEAD INVESTOR PRESENTATION AND Q&A SESSION WEDNESDAY, FEBRUARY 2nd AT 3PM PACIFIC STANDARD TIME

BLACKHAWK’S TERP WHOLESALE LLC RECEIVES STATE-ISSUED MICRO-BUSINESS LICENSE ALLOWING FOR RETAIL DELIVERY

BLACKHAWK GROWTH’S MINDBIO THERAPEUTICS ADVANCES MICRODOSING CLINICAL TRIAL TO 59 PATIENTS

BLACKHAWK GROWTH’S MINDBIO THERAPEUTICS COMPLETES SAFETY MILESTONE IN ITS PHASE 1 CLINICAL TRIALS

BLACKHAWK GROWTH’S MINDBIO THERAPEUTICS LOOKS TO EXPAND MICRODOSING CLINICAL TRIALS

BLACKHAWK GROWTH’S SUBSIDIARY MINDBIO THERAPEUTICS APPOINTS PATRICK MOHER AS ADVISOR

BLACKHAWK GROWTH’S MINDBIO THERAPEUTICS SUCESSFULLY PROGRESSED TO THE SECOND HALF OF THEIR PHASE 1 MICRODOSING CLINICAL TRIAL

BLACKHAWK’S MINDBIO THERAPEUTICS UTILIZES TRIP PHARMA TO BRING MICRODOSING TRIALS TO NORTH AMERICA

BLACKHAWK GROWTHS MINDBIO THERAPETUICS PLANS TO COMMERVIALIZE INTELLECTUAL PROPERTY GENERATED FROM UNIVERSITY OF AUCKLAND CLINICAL TRIAL IN PSYCHEDELIC THERAPY IN ADVANCED STAGE CANCER PATIENTS

BLACKHAWK GROWTH’S MINDBIO THERAPEUTICS OPENS WORLD CLASS FACILITY FOR THE PHARMACEUTICAL INDUSTRY

BLACKHAWK GROWTH’S SAC PHARMA ANNOUNCES RECORD AUGUST REVENUE OF CDN$460,000 AND INCLUDES OPERATIONAL UPDATE

BLACKHAWK GROWTH SUBSIDIARY, MINDBIO THERAPEUTICS, ACCELERATES PHASE 1 & PHASE 2 MICRODOSING CLINICAL TRIALS

BLACKHAWK GROWTH TO COMPLETE INVESTMENT IN PSYCHEDELIC AND WELLNESS COMPANY MINDBIO THERAPEUTICS PTY LTD.

BLACKHAWK GROWTH’S CANNABIS SUBSIDIARY SPACED FOOD PROVIDES INVESTORS WITH EARLY ACCESS TO SAMPLE PRODUCTS (NON- INFUSED)

BLACKHAWK GROWTH’S SUBSIDIARY SPACED FOOD COMPLETES SUCCESSFUL FIRST RUN OF CANNABIS INFUSED SORBET AND ADDS THREE NEW PRODUCTS